Adamas Pharmaceuticals, Inc.

200 articles about Adamas Pharmaceuticals, Inc.

• Emeryville's Adamas Pharmaceuticals Files For $69 Million IPO

  3/6/2014

• Forest Laboratories, Inc. And Adamas Pharmaceuticals Announce Forest’s Submission Of New Drug Application For Memantine Extended Release And Donepezil Fixed-Dose Combination For Alzheimer’s Disease

  3/4/2014

• Forest Laboratories, Inc. Files Lawsuit Against Several Companies For Infringement Of NAMENDA XR ® Patents

  2/3/2014

• Adamas Pharmaceuticals Bags $40 Million From Forest Laboratories, Inc. For Alzheimer's Drug NDA Filing

  1/9/2014

• Adamas Pharmaceuticals Presents Positive Clinical Data for ADS-5102, A Treatment for Levodopa-Induced Dyskinesia, at the World Parkinson's Congress

  10/2/2013

• Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease

  6/18/2013

• Adamas Pharmaceuticals to Report Positive Phase 2/3 Results For ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease

  6/10/2013

• Adamas Pharmaceuticals Announces Issuance of First U.S. Patent for Nurelin&#0153 (Amantadine HCl Extended Release) Program

  4/22/2013

• Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data From Its Nurelin&#0153 Program at American Academy of Neurology Conference

  3/20/2013

• Forest Laboratories, Inc. and Adamas Pharmaceuticals Form Alliance for Up to $160 Million

  11/14/2012

• Adamas Pharmaceuticals Presents Update On Nurelin(TM) Program at Cambridge Healthtech Institute's Parkinson's Conference

  6/4/2012

• Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease

  9/28/2011

• Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A

  4/28/2010

• Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains

  2/22/2010

• Adamas Pharmaceuticals Selects Veeva Systems, Inc.'s CRM to Support New Product Commercialization and Anticipated Growth

  10/28/2009

• In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses

  9/14/2009

• Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting

  9/3/2009

• Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions

  8/25/2009

• Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain

  8/18/2009

• Adamas Pharmaceuticals (JOBS) Raises $40 Million in Series D Financing

  8/18/2009